Shoulder Innovations, Inc. ((SI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shoulder Innovations, Inc. struck an upbeat tone on its latest earnings call, emphasizing strong revenue growth, expanding surgeon adoption and steady margin gains despite widening losses. Management highlighted accelerating commercial momentum, successful product launches and a solid cash position while acknowledging higher spending and near-term risks tied to seasonality and pricing mix.
Strong Top-Line Growth
Shoulder Innovations reported net revenue of $16.7 million for Q1 2026, a 65% increase year over year and 16% sequential growth. Management credited new surgeon adoption, higher procedure utilization and improved pricing for the outsized performance, underscoring that growth is coming from both deeper penetration and a broader customer base.
Raised Full-Year Guidance
On the back of the strong start, the company raised its full-year 2026 net revenue outlook to a range of $65 million to $68 million, up from $62 million to $65 million. The new guidance implies growth of 37% to 44% versus 2025, signaling confidence that current momentum can be sustained despite embedded seasonality and mix variability.
High and Improving Gross Margins
Gross margin reached 77.7% in Q1 2026, slightly above the 76.9% recorded a year earlier, reinforcing the high-margin profile of the business. Management expects similar margin levels over the rest of the year and sees further upside as cost-down programs and scale efficiencies work through the manufacturing base.
Surgeon Adoption and Volume Gains
Total implant volume rose to 2,184 units in the quarter, up 51% versus the prior year, reflecting growing procedure throughput. The company ended 2025 with 134 core and contender surgeons, a 61% increase, and noted it more than doubled the number of new customers entering its funnel compared with Q1 2025.
Commercial and Educational Momentum
Commercial activity was supported by 44 company-sponsored educational events in Q1, which are helping convert interest into active users. Attendance at the 2026 Napa symposium climbed more than 70% year over year, and over 70% of non-customer attendees have already performed or committed to their first or expanded cases.
Product and Technology Milestones
The I-135RFX humeral stem transitioned from limited release to full commercial launch, now including expanded fracture indications that broaden its clinical reach. The company also began a limited release of the N22 Glenosphere, surpassed 500 patients in its clinical registry and reported faster-than-expected progress on its micro-robotic partnership.
Cash Position and Fulfillment Strategy
Cash and cash equivalents stood at $108.5 million as of March 31, 2026, giving the company room to invest in growth. Management proactively boosted inventory and asset purchases to prevent supply bottlenecks as volumes rise and expects materially lower cash burn starting in the second quarter.
Widening Operating Losses
Despite robust revenue gains, net loss widened to $8.4 million in Q1 2026 from $4.7 million a year ago, reflecting the cost of scaling. Adjusted EBITDA loss similarly increased to $7.0 million from $3.5 million, as the company leaned into spending to build its commercial footprint and advance its pipeline.
Higher SG&A and R&D Spending
Selling, general and administrative expenses climbed to $18.2 million from $10.5 million, driven by additional commercial headcount and variable selling costs tied to higher activity. Research and development rose to $3.8 million from $1.6 million as new product initiatives and robotic development advanced, highlighting management’s emphasis on innovation.
Cash Burn and Working Capital
Q1 cash burn was elevated as the company built inventory and invested in assets to support anticipated demand, alongside working capital shifts. While these actions weighed on near-term liquidity, management argued they are front-loaded investments and reiterated expectations for lower cash burn beginning in Q2.
Seasonality and ASP/Mix Variability
The updated outlook factors in seasonal patterns, with lighter volumes expected in the third quarter and a step-up into the fourth quarter. Management also cautioned that average selling prices, which supported Q1 results, may fluctuate quarter to quarter based on product mix and payer dynamics, adding some near-term variability.
Evolution of Contender Surgeons
Growth in the “contender” surgeon category moderated in Q1 as more doctors converted into the core segment, which is part of the company’s strategy. While this evolution may compress near-term growth optics in that specific tier, management views it as a positive sign of deeper engagement and stickier customer relationships.
Forward-Looking Guidance and Outlook
Looking ahead, management expects full-year revenue of $65 million to $68 million, with gross margins holding near current levels despite product-mix and pricing swings. They anticipate SG&A as a percentage of revenue to tick up in the middle of the year before easing in Q4, R&D intensity to moderate later in 2026 and current cash reserves to be sufficient to support the path toward cash-flow breakeven.
Shoulder Innovations’ earnings call painted the picture of a fast-growing, high-margin business deliberately spending to secure long-term advantages. Investors will be watching whether the company can translate its accelerating surgeon adoption, robust product pipeline and sizable cash buffer into sustained growth while narrowing losses as scale and cost discipline kick in.